Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of non-statutory stock options for 42,425 shares to 17 new employees on March 15, 2022. This grant, part of the 2021 Inducement Equity Incentive Plan, serves as an inducement for employment acceptance, compliant with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $28.81 per share, equal to the closing price on the grant date. Options vest over four years, with different vesting schedules for U.S. and India-based hires.
Schrödinger is focused on enhancing drug discovery through its physics-based software platform.
Schrödinger, Inc. (Nasdaq: SDGR) announced promising preclinical data on its small-molecule Wee1 inhibitors, to be presented at the AACR Annual Meeting in New Orleans (April 8-13, 2022). These inhibitors may induce apoptosis in tumor cells by triggering DNA damage. Early studies show significant anti-tumor activity in ovarian and uterine cancers. Schrödinger plans to select a development candidate later this year, with an emphasis on strong pharmacodynamics and potential use as monotherapy or in combination therapy.
Schrödinger (Nasdaq: SDGR) announced its participation in the Truist Securities Life Sciences AI Symposium on March 1, 2022. Karen Akinsanya, Ph.D., will join a panel discussing technology-enabled drug discovery at 10:10 a.m. ET. An on-demand workshop titled “Transforming Molecular Design of Novel Drug,” hosted by Ramy Farid, Ph.D., will also be available. Access details for the panel and workshop can be found in the investors section of Schrödinger's website. Founded in 1990, Schrödinger employs over 650 individuals and focuses on innovative drug discovery through its physics-based software platform.
Schrödinger, Inc. (Nasdaq: SDGR) reported a strong fourth quarter with software revenue of $38.6 million, a 55% increase from Q4 2020. For the full year 2021, total revenue reached $137.9 million, up 28% year-over-year, with software revenue of $113.2 million, increasing 22%. The company provided a positive outlook for 2022, anticipating total revenue between $161 million and $181 million, and software revenue between $126 million and $136 million. Additionally, Schrödinger announced strategic goals including a Phase 1 clinical study of its MALT1 inhibitor.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options totaling 32,425 shares to 17 newly hired employees as part of its 2021 Inducement Equity Incentive Plan on February 14, 2022. These options, which have an exercise price of $26.99 per share, will vest over four years. The grants aim to attract talent, complying with Nasdaq Listing Rule 5635(c)(4). Schrödinger leverages its physics-based software platform for drug discovery and materials development, engaging with clients across over 70 countries.
Schrödinger (Nasdaq: SDGR) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. A conference call will take place at 4:30 p.m. ET. Interested parties can access the live webcast on Schrödinger’s website. The company focuses on a physics-based software platform that enhances therapeutic and materials discovery, used by various organizations globally. With over 500 employees and clients in more than 70 countries, Schrödinger aims to lower costs and speed up drug development.
Schrödinger (Nasdaq: SDGR) will present a company overview at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022, at 1:00 p.m. ET. The live presentation will be accessible via the company's website under the 'News & Events' section and will be archived for about seven days.
Founded in 1990, Schrödinger's software platform accelerates drug and materials discovery, engaging with over 500 employees and customers in over 70 countries.
On January 16, 2022, Schrödinger, Inc. (Nasdaq: SDGR) granted stock options to purchase 80,675 shares of common stock to 80 new employees, primarily in India. This action was part of the company’s 2021 Inducement Equity Incentive Plan and was approved by its compensation committee. The exercise price is set at $30.69 per share, matching the closing price on January 14, 2022. The options have a ten-year term and vest over four years. Schrödinger focuses on transforming therapeutic and material discovery through its innovative software platform.
Schrödinger, Inc. (Nasdaq: SDGR) has completed a $6 million all-cash acquisition of XTAL BioStructures, Inc. on January 14, 2022. This strategic acquisition enhances Schrödinger's capabilities in structure-based drug discovery by integrating structural biology services, including biophysical methods and X-ray crystallography. By bringing these services in-house, Schrödinger aims to improve its drug discovery programs through access to high-quality protein structures and bolster its product offerings with validated computational structures.
Schrödinger (Nasdaq: SDGR) will participate in a fireside chat at the H.C. Wainwright BioConnect Conference, with a pre-recorded presentation set for January 10, 2022, at 11:00 a.m. ET. The webcast will be available on-demand on Schrödinger’s website under "News & Events" and archived for seven days. The company is known for its physics-based software platform that accelerates the discovery of therapeutics and materials. Founded in 1990, Schrödinger employs over 500 staff and collaborates globally.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
